225 related articles for article (PubMed ID: 23160941)
1. Functional characterization of three mouse formyl peptide receptors.
He HQ; Liao D; Wang ZG; Wang ZL; Zhou HC; Wang MW; Ye RD
Mol Pharmacol; 2013 Feb; 83(2):389-98. PubMed ID: 23160941
[TBL] [Abstract][Full Text] [Related]
2. Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils.
Southgate EL; He RL; Gao JL; Murphy PM; Nanamori M; Ye RD
J Immunol; 2008 Jul; 181(2):1429-37. PubMed ID: 18606697
[TBL] [Abstract][Full Text] [Related]
3. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.
He R; Tan L; Browning DD; Wang JM; Ye RD
J Immunol; 2000 Oct; 165(8):4598-605. PubMed ID: 11035102
[TBL] [Abstract][Full Text] [Related]
4. RhoA/ROCK downregulates FPR2-mediated NADPH oxidase activation in mouse bone marrow granulocytes.
Filina JV; Gabdoulkhakova AG; Safronova VG
Cell Signal; 2014 Oct; 26(10):2138-46. PubMed ID: 24880063
[TBL] [Abstract][Full Text] [Related]
5. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR.
Rabiet MJ; Huet E; Boulay F
Eur J Immunol; 2005 Aug; 35(8):2486-95. PubMed ID: 16025565
[TBL] [Abstract][Full Text] [Related]
6. A novel nonpeptide ligand for formyl peptide receptor-like 1.
Nanamori M; Cheng X; Mei J; Sang H; Xuan Y; Zhou C; Wang MW; Ye RD
Mol Pharmacol; 2004 Nov; 66(5):1213-22. PubMed ID: 15308762
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants for the interaction of formyl peptide receptor 2 with peptide ligands.
He HQ; Troksa EL; Caltabiano G; Pardo L; Ye RD
J Biol Chem; 2014 Jan; 289(4):2295-306. PubMed ID: 24285541
[TBL] [Abstract][Full Text] [Related]
8. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for recognition of N-formyl peptides as pathogen-associated molecular patterns.
Chen G; Wang X; Liao Q; Ge Y; Jiao H; Chen Q; Liu Y; Lyu W; Zhu L; van Zundert GCP; Robertson MJ; Skiniotis G; Du Y; Hu H; Ye RD
Nat Commun; 2022 Sep; 13(1):5232. PubMed ID: 36064945
[TBL] [Abstract][Full Text] [Related]
10. The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist.
Sogawa Y; Shimizugawa A; Ohyama T; Maeda H; Hirahara K
J Pharmacol Sci; 2009 Nov; 111(3):317-21. PubMed ID: 19926937
[TBL] [Abstract][Full Text] [Related]
11. The formyl peptide fMLF primes platelet activation and augments thrombus formation.
Salamah MF; Ravishankar D; Vaiyapuri R; Moraes LA; Patel K; Perretti M; Gibbins JM; Vaiyapuri S
J Thromb Haemost; 2019 Jul; 17(7):1120-1133. PubMed ID: 31033193
[TBL] [Abstract][Full Text] [Related]
12. Structural Determinants in the
Viklund M; Fredriksson J; Holdfeldt A; Lind S; Franzyk H; Dahlgren C; Sundqvist M; Forsman H
J Immunol; 2022 Apr; 208(7):1632-1641. PubMed ID: 35321878
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of formyl peptide receptor 1 and 2 is associated with increased inflammation and enhanced liver injury after LPS-stimulation.
Giebeler A; Streetz KL; Soehnlein O; Neumann U; Wang JM; Brandenburg LO
PLoS One; 2014; 9(6):e100522. PubMed ID: 24956481
[TBL] [Abstract][Full Text] [Related]
14. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor.
Dahlgren C; Christophe T; Boulay F; Madianos PN; Rabiet MJ; Karlsson A
Blood; 2000 Mar; 95(5):1810-8. PubMed ID: 10688842
[TBL] [Abstract][Full Text] [Related]
15. Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors.
Quehenberger O; Prossnitz ER; Cavanagh SL; Cochrane CG; Ye RD
J Biol Chem; 1993 Aug; 268(24):18167-75. PubMed ID: 8349692
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of a bifunctional ligand of the formyl peptide receptor1 fused to the myc epitope.
Charest-Morin X; Roy C; Fernandes MJ; Marceau F
Int Immunopharmacol; 2015 Mar; 25(1):229-34. PubMed ID: 25681283
[TBL] [Abstract][Full Text] [Related]
17. Formyl-peptide receptor 2 governs leukocyte influx in local
Weiss E; Hanzelmann D; Fehlhaber B; Klos A; von Loewenich FD; Liese J; Peschel A; Kretschmer D
FASEB J; 2018 Jan; 32(1):26-36. PubMed ID: 28855276
[TBL] [Abstract][Full Text] [Related]
18. Structural changes of the ligand and of the receptor alters the receptor preference for neutrophil activating peptides starting with a formylmethionyl group.
Forsman H; Winther M; Gabl M; Skovbakke SL; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2015 Jan; 1853(1):192-200. PubMed ID: 25447672
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Quin-C1 for its anti-inflammatory property in a mouse model of bleomycin-induced lung injury.
He M; Cheng N; Gao WW; Zhang M; Zhang YY; Ye RD; Wang MW
Acta Pharmacol Sin; 2011 May; 32(5):601-10. PubMed ID: 21499285
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and characterization of fMLF-mimicking AApeptides.
Hu Y; Cheng N; Wu H; Kang S; Ye RD; Cai J
Chembiochem; 2014 Nov; 15(16):2420-6. PubMed ID: 25224835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
